Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 1, 2024ChemistrySelect

Design, Synthesis, and Evaluation of Quinoline‐1,2,3‐Triazole Hybrids as CYP51 Inhibitors: In Silico Study and In Vitro Antimicrobial Assessment

View Full Paper
Ask AI
Bookmark
Share

Authors

BCBhadreshkumar K. ChabhadiyaHNHem N. NaikBMBhavika A. Mohite

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Chabhadiya et al. (2024) studied this question.

synapsesocial.com/papers/68e59c4cb6db643587536907https://doi.org/10.1002/slct.202402221
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Synthesis, Docking, and Biological Properties of 2-Phenyl-5,6,7,8-tetrahydroquinazoline-4(3H)-thione Derivatives2026
  2. 2Design, synthesis, in silico docking, and DFT analysis of 1,2,3–triazoles containing quinoxaline hybrids as effective antimicrobial agents2026
  3. 3Synthesis of Novel 2-Quinolone linked 1,2,3-Triazole Derivatives as Potent Antimicrobial Activities: in silico Docking Studies2024
  4. 4Fused Thiazolo[2,3‐<i>b</i>]Quinazolinone–Chromone Hybrids: Synthesis, Characterization, In Vitro Antibacterial Activity and In Silico Screening2024 · 4 citations
  5. 5New Quinazolinone‐Tethered 1,2,3‐Triazoles aSs Potent Antimicrobial Agents: Design, Synthesis, Biological Evaluation and in silico Docking Study2024 · 1 citations